Show simple item record

dc.contributor.authorAldana, P.C.
dc.contributor.authorDriscoll, M.S.
dc.date.accessioned2019-12-04T15:55:06Z
dc.date.available2019-12-04T15:55:06Z
dc.date.issued2019
dc.identifier.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85075534831&doi=10.1016%2fj.ijwd.2019.09.007&partnerID=40&md5=939ffb1e2ed7048a6ca6cd1ceed5d2dd
dc.identifier.urihttp://hdl.handle.net/10713/11477
dc.description.abstractHidradenitis suppurativa (HS) is a chronic inflammatory skin condition that disproportionately affects women and is associated with significant physical and psychosocial impact. Recent studies have reported an increased prevalence of substance abuse among patients with HS, including increased alcohol, opioid, and cannabis use. Whether substance use disorder is more prevalent among patients with HS is controversial because these data come from small studies and a major confounder is that patients with HS are often prescribed opioids for HS-associated pain. This review summarizes the current literature on substance use in HS to investigate whether substance use disorder is more likely in this patient population. We also highlight possible cofounders and areas of unmet need in HS that are potential causes of abuse, such as adequate pain control and impaired quality of life, and suggest opportunities for provider intervention. Evidence suggests that there is an increased prevalence of substance use disorder in patients with HS, but the full extent is still difficult to determine. However, with early screening and appropriate referrals to specialists, dermatologic providers may properly intervene and prevent substance use disorder in patients with HS.en_US
dc.description.sponsorshipThis study was supported in part by Yale School of Medicine, Office of Student Research.en_US
dc.description.urihttps://doi.org/10.1016/j.ijwd.2019.09.007en_US
dc.language.isoen_USen_US
dc.publisherElsevier Incen_US
dc.relation.ispartofInternational Journal of Women's Dermatology
dc.subjectAlcoholen_US
dc.subjectCannabisen_US
dc.subjectHidradenitis suppurativaen_US
dc.subjectOpioiden_US
dc.subjectPainen_US
dc.subjectPsychosocial healthen_US
dc.subjectSubstance abuseen_US
dc.titleIs substance use disorder more prevalent in patients with hidradenitis suppurativa?en_US
dc.typeArticleen_US
dc.identifier.doi10.1016/j.ijwd.2019.09.007


Files in this item

Thumbnail
Name:
Publisher version

This item appears in the following Collection(s)

Show simple item record